Verastem Oncology (NASDAQ:VSTM) announced on Wednesday that the U.S. FDA has cleared the investigational new drug application ...

Groundbreaking longevity research initiative brings together leading scientists and institutions to decode the genetic basis ...

Vera Therapeutics, Inc.’s VERA share price has surged by 6.17%, which has investors questioning if this is right time to sell.

STATEN ISLAND, N.Y. -- While the Seaview Avenue redesign — officially unveiled by the city earlier this month — was met with ...

Protagonist Therapeutics, Inc.’s PTGX share price has surged by 6.71%, which has investors questioning if this is right time to sell.

Highlights,Wellington Management Group LLP reduced its holdings in Vera Therapeutics during the fourth quarter.,Schroder Investment Management and Pictet Asset Management increased their equity ...

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

You’ve viewed 1 of 5 articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.

BOSTON — Sparsentan, a first-in-class, oral dual endothelin-angiotensin receptor antagonist, shows significant benefit in reducing proteinuria in the difficult-to-manage focal segmental ...

BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of ...

BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting ...